Asthma - severe allergic asthma - paediatric patient

The PBS subsidises omalizumab for paediatric patients with uncontrolled severe allergic asthma.

Patient eligibility

Treatment with omalizumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 100 for paediatric patients with uncontrolled severe allergic asthma.

Patients must be eligible for the PBS and meet the relevant restrictions criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing omalizumab.

Section 100 arrangements

This item is only available for day admitted patients, non-admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

This item is not PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Toxicity and severity descriptors

Use the toxicity and severity descriptors for severe allergic asthma with the authority application when demonstrating a patient’s intolerance to prior treatments.

Applications

All applications must be completed by a:

  • treating paediatric respiratory physician
  • clinical immunologist
  • allergist
  • paediatrician, or
  • general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised omalizumab for the treatment of paediatric patients with uncontrolled severe allergic asthma in writing and:

All applications must include the completed:

Medical practitioners should request the appropriate maximum quantity and number of repeats to provide an initial course of omalizumab of up to 28 weeks, including the recommended number of doses for the patient’s baseline IgE level and body weight.

Continuing treatment

Make all applications for continuing authority approval to prescribe PBS subsidised omalizumab for the treatment of paediatric patients with uncontrolled severe allergic asthma in writing and:

All applications must include the completed:

Recommencing treatment

Patients who want to start a subsequent treatment cycle after a break in PBS subsidised omalizumab of at least 6 months must:

  • requalify for initial treatment and
  • meet the relevant criteria at that time

Further information

Call the PBS Complex Drugs Programs enquiry line

Page last updated: 5 July 2018